NUVB (Nuvation Bio) Retained Earnings: $-1,172.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NUVB Nuvation Bio Inc NUVB
32 GF Score
Price $6.42
! 3 Warning Signs
View Full Analysis

What is Nuvation Bio Retained Earnings?

Nuvation Bio NUVB +0.78% 32 Retained Earnings is $-1,172.8 Mil as of Jun. 2026. GuruFocus rates NUVB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Nuvation Bio's retained earnings for the quarter that ended in Jun. 2026 was $-1,172.8 Mil.

Nuvation Bio's quarterly retained earnings increased from Dec. 2025 ($-1,115.4 Mil) to Mar. 2026 ($-1,110.0 Mil) but then declined from Mar. 2026 ($-1,110.0 Mil) to Jun. 2026 ($-1,172.8 Mil).

Nuvation Bio's annual retained earnings declined from Dec. 2023 ($-342.8 Mil) to Dec. 2024 ($-910.7 Mil) and declined from Dec. 2024 ($-910.7 Mil) to Dec. 2025 ($-1,115.4 Mil).


Nuvation Bio  (NYSE:NUVB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Nuvation Bio Retained Earnings Historical Data

* Premium members only.

The historical data trend for Nuvation Bio's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvation Bio Retained Earnings Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -162.80 -267.00 -342.80 -910.74 -1,115.37

Nuvation Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,022.99 -1,078.78 -1,115.37 -1,109.97 -1,172.81
NUVB
32GF Score
Nuvation Bio Inc NUVB
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuvation Bio Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-1,172.8 Mil mean?
Nuvation Bio (NUVB) has a Retained Earnings of $-1,172.8 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Nuvation Bio and its competitors.
Is Nuvation Bio's Retained Earnings too high?
Nuvation Bio's current Retained Earnings is $-1,172.8 Mil. Overall, Nuvation Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Retained Earnings compare to IOVA and SLS?
Nuvation Bio's Retained Earnings of $-1,172.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Nuvation Bio and its competitors. Nuvation Bio's current Retained Earnings is $-1,172.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current Retained Earnings of $-1,172.8 Mil. The current Retained Earnings is $-1,172.8 Mil. Nuvation Bio's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current Retained Earnings is $-1,172.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvation Bio Business Description

Other Exchanges 1E30:Germany
Address 1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
32GF Score

Get the complete analysis for NUVB

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.42
Price